An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2508-2515

  Ter Heine, Rob ^a   Van Waterschoot, Robert A B ^b   Keizer, Ron J ^a   Beijnen, Jos H ^a   Schinkel, Alfred H ^b   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

ADME; Bioavailability; Computational ADME; Cytochrome P450; Drug interactions; Drug metabolizing enzymes

Indexed keywords

CYTOCHROME P450 3A4; LOPINAVIR; RITONAVIR;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME ACTIVITY; FIRST PASS EFFECT; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 79954560262     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22457     Document Type: Article

References (11)

1. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR. 1999. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 27:902-908.
2. Kumar GN, Jayanti VK, Johnson MK, Uchic J, Thomas S, Lee RD, Grabowski BA, Sham HL, Kempf DJ, Denissen JF, Marsh KC, Sun E, Roberts SA. 2004. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 21:1622-1630.
3. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42:3218-3224.
4. Ernest CS, Hall SD, Jones DR 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
5. van Herwaarden AE, Wagenaar E, Van Der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, Van Der Valk MA, van, Van Der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. 2007. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592.
6. van Waterschoot RA, ter Heine R, Wagenaar E, Van Der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH. 2010. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160:1224-1233.
7. ter Heine R, Alderden-Los C, Rosing H, Hillebrand M, van Gorp E, Huitema A, Beijnen J. 2007. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: Method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 21:2505-2514.
8. Jonsson EN, Karlsson MO. 1999. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64.
9. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN)-A Perl module for NONMEM related programming. Comput Methods Programs Biomed 75:85-94.
10. Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH. 2005. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 60:378-389.
11. Ng J, Causemaker S, Xiong J, Chiu Y, Wikstrom K, Doan T, Podsadecki T, Bernstein B. 2008. A comparison of the single dose bioavailability of a ritonavir tablet formulation relative to the ritonavir soft gelatin capsule in healthy adult subjects. XVII International AIDS Conference August 2008 Poster #TUPE0076